ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANCA associated vasculitis"

  • Abstract Number: 1767 • ACR Convergence 2025

    Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis

    Claire Galand1, Fei Liu2, Katherine Vernon2, Ravi Vats2, Christine Lian3, V. Michael Holers4, H. Terence Cook5, David Cuthbertson6, Nader Khalidi7, Curry Koening8, Carol Langford9, Carol McAlear10, Paul Monach11, Christian Pagnoux12, Jason Campagna2, Shelia Violette2 and Peter Merkel10, 1Q32 Bio Inc,, Waltham, MA, 2Q32 Bio Inc, Waltham, MA, 3Department of Pathology, Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, 4University of Colorado Anschutz Medical Campus, Aurora, 5Department of Immunology and Inflammation, Imperial College London, London, United Kingdom, 6University of South Florida, Tampa, 7McMaster University, Hamilton, ON, Canada, 8University of Texas Dell Medical School, Austin, TX, 9Cleveland Clinic, Moreland Hills, OH, 10University of Pennsylvania, Philadelphia, PA, 11VA Boston Healthcare System, Boston, MA, 12Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: One proposed mechanism of tissue damage in ANCA-associated vasculitis (AAV) is the formation of neutrophil extracellular traps (NETs) during extravasation of neutrophils into and…
  • Abstract Number: 1602 • ACR Convergence 2025

    Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis

    Irene Carrión-Barberà1, Jorge A. Gonzalez-Chapa2, David Cuthbertson3, Nader Khalidi4, Curry Koening5, Carol Langford6, Carol McAlear7, Paul Monach8, Larry Moreland9, Christian Pagnoux10, Philip Seo11, Ulrich Specks12, Kenneth Warrington12, Peter Merkel7 and Christian Lood2, 1Department of Rheumatology. Hospital del Mar, Barcelona, Spain, 2University of Washington, Division of Rheumatology, Seattle, 3University of South Florida, Tampa, 4Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, 5University of Texas Dell Medical School, Austin, TX, 6Cleveland Clinic, Moreland Hills, OH, 7University of Pennsylvania, Philadelphia, PA, 8VA Boston Healthcare System, Boston, MA, 9University of Colorado, Denver, CO, 10Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, 11Johns Hopkins University, Baltimore, MD, 12Mayo Clinic, Rochester, MN

    Background/Purpose: Innate immune activation plays a key role in granulomatosis with polyangiitis (GPA), contributing to vascular inflammation via neutrophil extracellular traps, immune complexation (IC), and…
  • Abstract Number: 0718 • ACR Convergence 2025

    Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden

    Hanna Lindberg1, Klytaimnistra Voudouri1, Lars Lindhagen1, Maria K Svensson2, Ann Knight1 and Johanna Dahlqvist3, 1Uppsala University, Uppsala, Sweden, 2Uppsala University, Uppsala, 3Uppsala University Hospital, Uppsala, Sweden

    Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are rare yet severe autoimmune diseases. Previous studies have indicated that patients with AAV have an increased risk…
  • Abstract Number: 0150 • ACR Convergence 2025

    Mortality in Anca-associated Vasculitis

    Fabricio Benavides Villanueva1, Vanesa Calvo-Río2, Diana Prieto-Peña3, Monica Renuncio-García4, Adrian Martin-Gutierrez5, Amparo Sanchez-Lopez6, Claudia Poo-fernandez7, Clara Escagedo-Cagigas8, maria Rodríguez-Vidriales8 and Ricardo Blanco2, 1Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, 2Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, 4Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, 5Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, 6Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, 7Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, 8Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). Mortality rates are scare,…
  • Abstract Number: 2517 • ACR Convergence 2025

    Predictors for Mortality in Patients Who Received Plasmapheresis for Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis

    Sai Shanmukha Sreeram Pannala1, Medha Rajamanuri2, Srikar Sama3, Fares Saliba4, Omar Mourad5, Koushik Varma Sangaraju6, Veena Katikineni7 and Anastasia Slobodnick8, 1Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, staten island, new york city, NY, 2Southern Illinois University School of Medicine, Springfield, IL, 3University of California San Francisco Fresno, Fresno, CA, 4Staten Island University Hospital, Staten Island, NY, 5Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, Staten Island, NY, 6St. Luke's University Health Network, Bethlehem, PA, 7Desert Orthopaedic and Rheumatologic Institute, Apple Valley, CA, 8Northwell, Staten Island, NY

    Background/Purpose: Plasmapheresis (PLEX) has a compelling rationale in its ability to remove pathogenic ANCAs, in the management of ANCA-associated vasculitis (AAV), particularly in patients with…
  • Abstract Number: 1768 • ACR Convergence 2025

    TREM-1 and TREM-2 Define Inflammatory and Protective Axes in ANCA-Associated Glomerulonephritis

    Lea Dionet1, Alexandre Lanau2, Paul Breillat3, Quentin Delcros4, Federica Pallotti5, Margot Poux6, Pierre Isnard1, Arthur Lavigne4, Xavier Puéchal7, alexandre karras8, Jean-Paul Duong9, Olivia Lenoir10, Pierre-Louis Tharaux11 and Benjamin Terrier12, 1INSERM, Paris, France, 2Institut Curie, Paris, France, 3INSERM, PARIS 17, Ile-de-France, France, 4AP-HP, Paris, France, 5Internal Medicine and Clinical Immunology, Rennes, France, 6Université de Paris, PARIS 04EME, France, 7Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( 75014 ), Ile-de-France, France, 8HEGP - assistance publique hopitaux de paris, paris, France, 9INSERM, Paris, 10Paris Cardiovascular Research Center, Université Paris Cité, INSERM U970, Paris, France, PARIS, Ile-de-France, France, 11Paris Cardiovascular Research Center, Université Paris Cité, INSERM U970, Paris, France, PARIS, France, 12Cochin Hospital, Paris, France

    Background/Purpose: ANCA-associated vasculitis (AAV) is a small-vessel vasculitis that can lead to life-threatening renal injury. Neutrophils, monocytes and macrophages play a pivotal role not only…
  • Abstract Number: 1600 • ACR Convergence 2025

    Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study

    Fabricio Benavides Villanueva1, Andrea Tristan-Alonso2, Carlos Martinez-Rivera3, Alicia Padilla-Galo4, Marina Blanco-Aparicio5 and Ricardo Blanco6, 1Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, 2Division of Pneumology, Hospital Universitario Puerta del Hierro, Madrid, Spain, Majadahonda, Madrid, Spain, 3Division of Pneumology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, Barcelona, Catalonia, Spain, 4Division of Pneumology, Hospital Universitario Virgen de la Victoria, Málaga, Spain, Malaga, Andalucia, Spain, 5Division of Pneumology, Hospital Universitario A Coruña, A Coruña, Spain, A coruña, Galicia, Spain, 6Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: Benralizumab is approved for eosinophil-driven conditions, like eosinophilic asthma. Recently, the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) authorized its…
  • Abstract Number: 0716 • ACR Convergence 2025

    Utility of Follow-Up Cardiac Magnetic Resonance Imaging In Patients With Eosinophilic Granulomatosis With Polyangiitis

    Chelsea Cheng1, Justine Lafleur-Careau2, Navneet Kang1, Medha Soowamber3 and Christian Pagnoux3, 1Mount Sinai Hospital, Toronto, Canada, 2Mount Sinai Hospital, Saint-Augustin-de-Desmaures, Canada, 3Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystem disorder characterized by asthma, rhinitis, peripheral blood eosinophilia, and necrotizing vasculitis of small vessels. Cardiac…
  • Abstract Number: 2516 • ACR Convergence 2025

    Mortality Trends in Primary Systemic Vasculitis in the United States (1999–2023)

    Rameez Qasim1, Sabah Mohib2, Muhammad Ali3 and Khadija Mohib4, 1Allama Iqbal Medical College Lahore, Lahore, Pakistan, 2N/A, Reseda, CA, 3Dow International Medical College, Karachi, Sindh, Pakistan, 4Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV

    Background/Purpose: Primary systemic vasculitides comprise a group of immunological disorders that inflame blood vessel walls and are categorized by the size of the blood vessels…
  • Abstract Number: 1766 • ACR Convergence 2025

    Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study

    caterina ricordi1, Maxime Beydon2, Johanne Liberatore3, Pascal Cohen4, bertrand Dunogue5, Camille Mettler6, Benjamin Torreau7, Luc Mouthon5, Xavier Puéchal8 and Benjamin Terrier9, 1Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, 2Sorbonne University, INSERM, Institut Pierre Louis of Epidemiology and Public Health, Equipe PEPITES, Pitié Salpêtrière Hospital, Service of Public Health, Centre of Pharmacoepidemiology (Cephepi), Paris, France, 3Department of Internal Medicine, Centre Hospitalier d’Angouleme, Angouleme, France, 4Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, 5Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, 6Department of Internal Medicine, Hôpital Bichat - Claude-Bernard, Paris, France, 7Internal Medicine and Immunology, CHU Tours, Tours, France, 8Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( 75014 ), Ile-de-France, France, 9Cochin Hospital, Paris, France

    Background/Purpose: Rituximab (RTX) is the standard of care for both induction and maintenance in ANCA-associated vasculitides (AAVs). While CD19 B-cell monitoring is used to evaluate…
  • Abstract Number: 1598 • ACR Convergence 2025

    Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study

    caterina ricordi1, elena treppo2, Pavel Novikov3, Paul Russo4, Luca moroni5, Angelo Fassio6, Paolo Delvino7, hervé lobbes8, Chiara Marvisi1, Francesco Muratore1, Xavier Puéchal9, Carlo Salvarani1 and Benjamin Terrier10, 1Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, 2Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, 3Sechenov University, Moscow, Russia, 4Royal Adelaide Hospital, Clinical Immunology and Allergy, Adelaide, Australia, 5IRCCS San Raffaele, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milan, Italy, 6University of Verona, Department of Medicine, Unit of Rheumatology, Verona, Italy, 7University of Milano-Bicocca, Monza, Monza and Brianza, Italy, 8Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, 9Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( 75014 ), Ile-de-France, France, 10Cochin Hospital, Paris, France

    Background/Purpose: Medium- and small-vessel vasculitides (MVV and SVV) are a heterogeneous group of inflammatory diseases affecting the vascular wall. Current treatment strategies are based on…
  • Abstract Number: 0713 • ACR Convergence 2025

    Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms

    Adil Vural1, Chao Zhang2, Yaseen Kinanah1, Cassandra Calabrese3 and Adam Brown4, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland Heights, OH, 3Cleveland Clinic Foundation, Cleveland Heights, OH, 4Cleveland Clinic, Shaker Heights, OH

    Background/Purpose: ANCA associated vasculitis (AAV) is a severe autoimmune disorder with substantial morbidity and mortality. Establishing the diagnosis might be challenging due to the existence…
  • Abstract Number: 0724 • ACR Convergence 2024

    Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study

    Fabricio Benavides1, Alba Herrero-Morant2, Salma Al Fazazi3, Vanesa Calvo-Rio4, Mónica Renuncio-García5, Adrián Martín-Gutiérrez6, Amparo Sánchez-López7, Claudia Poo-fernandez7, Clara Escagedo-Cagigas7, Maria Rodríguez-Vidriales1 and Ricardo Blanco-Alonso8, 1Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, 3Hospital Universitario Virgen de la Victoria, Málaga, Andalucia, Spain, 4Valdecilla Hospital, Santander, Cantabria, Spain, 5Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 7Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 8Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) is a group of vasculitis that affect small vessels. Includes Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with…
  • Abstract Number: 1254 • ACR Convergence 2024

    The Impact of Eosinophilic Granulomatosis with Polyangiitis on the Health-Related Quality of Life of Patients and Their Ability to Work: Evidence from a Real-World Survey in Clinical Practice

    Robert Spiera1, Paul Dolin2, Anat Shavit2, Jennifer Rowell3, Chris Edmonds4, Josefine Persson5, Danuta Kielar6, Daniel Mascia7, James Siddall7, Tia Pennant7, Fritha Hennessy7 and Stephanie Y. Chen8, 1Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Market Access and Pricing, AstraZeneca, Gothenburg, Sweden, 6Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, 7Adelphi Real World, Bollington, United Kingdom, 8BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody-associated vasculitis that confers significant disease burden. This real-world study described the impact of…
  • Abstract Number: 1607 • ACR Convergence 2024

    Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

    Sebastian Klapa1, Sabrina Arnold2, Antje Müller2, Andreas Koch3, Anja Staehle4, Wataru Kähler3, Harry Heidecke5, Gabriela Riemekasten2 and Peter Lamprecht2, 1University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, 2University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, 3Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, 4University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, 5CellTrend GmbH, Luckenwalde, Germany

    Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology